AI Summary Tecentriq (atezolizumab) is a PD-L1 inhibitor immunotherapy commonly used with Avastin as a first-line treatment for unresectable or metastatic hepatocellular carcinoma.
Medically reviewed.
Tecentriq (atezolizumab) is a prescription immunotherapy used to treat several types of cancer, including unresectable or advanced hepatocellular carcinoma (HCC). It is a PD-L1 inhibitor, a medicine that helps the immune system recognize and attack cancer cells. Tecentriq is commonly used with Avastin (bevacizumab) as a first-line treatment for eligible people with advanced liver cancer. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Tecentriq's role in liver cancer care: how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Tecentriq fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT TECENTRIQ TREATMENT
Tecentriq is a prescription medicine that contains atezolizumab. It belongs to a class of medications called PD-L1 inhibitors, a type of immunotherapy. Immunotherapy helps the body's immune system recognize and attack cancer cells.
Tecentriq is used to treat several types of cancer. In liver cancer, it is used for unresectable or advanced hepatocellular carcinoma (HCC). "Unresectable" means the cancer cannot be removed with surgery. Tecentriq is commonly combined with Avastin (bevacizumab) as a first-line treatment for eligible people, meaning the first medicine tried.
Tecentriq is given as ongoing therapy by a healthcare professional. Your care team checks your liver function and treatment response regularly, for example with Liver Function Tests (LFTs).
WHO TECENTRIQ MAY BE SUITABLE FOR
Eligibility for Tecentriq depends on your diagnosis, the stage of your cancer, your liver function, and your overall health. Your healthcare provider may prescribe Tecentriq if you have unresectable or metastatic hepatocellular carcinoma and your cancer cannot be treated with surgery or local therapies alone. You also need adequate liver function and overall health for systemic therapy, which is medicine that travels through the whole body.
For people with advanced HCC and preserved liver function, atezolizumab plus bevacizumab and durvalumab plus tremelimumab are preferred first-line options.
Every patient's health profile is different. Treatment decisions should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Tecentriq may be considered for adults with the following conditions or treatment goals:
Before recommending Tecentriq, healthcare providers evaluate several factors to decide whether it is an appropriate option, including:
HOW TECENTRIQ CAN HELP
Tecentriq blocks a protein called PD-L1 on cancer cells. Cancer cells can use PD-L1 to avoid detection by the immune system. Blocking it helps restore the immune system's ability to recognize cancer cells and increases the activity of T-cells, the immune cells that attack tumors.
This action helps slow tumor growth and progression. For some people, it may produce durable anti-cancer responses, meaning tumor control that lasts.
Tecentriq is commonly paired with Avastin, which works differently by blocking the blood vessel growth that feeds tumors. Your care team monitors liver function and treatment response throughout therapy.
LIVER CANCER CARE
Cancer cells can use a protein called PD-L1 to avoid detection by the immune system. Tecentriq blocks PD-L1 on the surface of liver cancer cells. This helps restore the immune system's ability to recognize the cancer and attack it.
Tecentriq increases the activity of T-cells, the immune cells that attack tumors. With more T-cell activity against the cancer, tumor growth and progression may slow.
Tecentriq and Avastin (bevacizumab) act on the cancer in different ways. Tecentriq works through the immune system, and Avastin blocks the blood vessel growth that feeds tumors. Both are systemic treatments, meaning they reach cancer throughout the body.
Tecentriq helps the immune system fight advanced liver cancer. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Tecentriq is prepared and given by a healthcare professional in a clinical setting. You do not prepare or inject it yourself.
For unresectable or metastatic hepatocellular carcinoma, Tecentriq is commonly given as 1,200 mg by vein every 3 weeks, together with Avastin (bevacizumab) 15 mg/kg by vein every 3 weeks. Your healthcare provider determines the right dose for you.
Tecentriq is given as an intravenous (IV) infusion, not a pill or a shot. The first infusion usually takes about 60 minutes. If you tolerate it well, later infusions may take about 30 minutes.
Tecentriq is ongoing therapy for advanced HCC. It continues until the cancer progresses, side effects become unacceptable, or your provider decides to stop. Duration is individualized and may range from months to years, depending on your response.
Healthcare professionals store and handle Tecentriq according to the manufacturer's recommendations. You do not need to store it at home.
Your care team regularly checks your liver function, how well treatment is working, and signs of immune-related side effects. Attend all infusion and monitoring appointments.
BENEFITS AND SAFETY
Tecentriq (atezolizumab) helps the immune system attack liver cancer cells. For some people with advanced HCC, it leads to long-lasting tumor control. The extent of benefit varies from person to person, depending on the cancer, liver function, and how the body responds. Tecentriq is commonly used with Avastin, and it works best as part of a care plan that includes regular monitoring, such as Liver Function Tests (LFTs).
As with any medication, Tecentriq may cause side effects. Some are mild, such as fatigue or rash. Others involve immune-related inflammation in organs such as the liver, lungs, or thyroid. Your healthcare provider will monitor you throughout therapy and adjust your care plan as needed.
BENEFITS
Tecentriq is an immunotherapy, so it offers people with advanced HCC a treatment that helps the immune system attack cancer cells.
Some people experience long-lasting tumor control, and Tecentriq may produce durable anti-cancer responses. How long a response lasts, and how strong it is, varies from person to person.
Tecentriq with Avastin is a standard first-line treatment for eligible people with advanced HCC. Atezolizumab plus bevacizumab is a preferred first-line option for people with advanced HCC and preserved liver function.
Tecentriq is commonly used with Avastin for improved outcomes. Your healthcare provider decides whether this combination suits you.
Report new or worsening symptoms to your care team promptly. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support to ensure safe use.
SUPPORTING YOUR RESULTS
Everyday habits are an important part of care alongside Tecentriq. Reporting symptoms early helps your care team catch immune-related inflammation quickly.
Staying hydrated, eating balanced meals, and keeping every infusion and monitoring appointment can support how your body handles treatment.
Areas that may support treatment:
common questions
Tecentriq (atezolizumab) is used to treat unresectable or advanced hepatocellular carcinoma (HCC), a type of liver cancer. It is an immunotherapy that blocks the PD-L1 protein on cancer cells, which helps your immune system recognize and attack them. For eligible people, it is commonly given with Avastin (bevacizumab) as a first-line treatment. Ask your healthcare professional whether this approach fits your diagnosis and care goals.
Tecentriq may be considered for adults with unresectable or metastatic HCC that cannot be treated with surgery or local therapies alone. You also need adequate liver function and overall health for systemic therapy, meaning medicine that travels through the whole body. Your provider checks whether immunotherapy-based treatment suits you. Only a healthcare professional can decide if Tecentriq is right for you, after a full assessment of your liver condition and treatment goals.
A healthcare professional gives Tecentriq by intravenous (IV) infusion in a clinical setting, so you do not prepare or inject it yourself. For HCC, it is commonly given as 1,200 mg every 3 weeks together with Avastin. The first infusion usually takes about 60 minutes, and later ones may take about 30 minutes if you tolerate it. Your provider sets your exact dose and schedule.
Treatment length is individualized and may range from months to years, depending on your response. Tecentriq is ongoing therapy that continues until the cancer progresses, side effects become unacceptable, or your healthcare provider decides to stop. Regular monitoring of liver function and treatment response guides these decisions. Do not stop treatment on your own. Talk with your care team about what to expect in your case.
Tecentriq can help slow tumor growth, and some people have long-lasting tumor control. It works by restoring the immune system's ability to recognize cancer cells and by increasing T-cell activity. It is commonly used with Avastin for improved outcomes. Results vary from person to person, depending on the cancer, liver function, and how your body responds. Ask your healthcare professional what you can realistically expect.
Common side effects of Tecentriq include fatigue, decreased appetite, rash or itching, and diarrhea. It can also cause immune-related inflammation in organs such as the liver, lungs, or thyroid. Tell your care team promptly about cough, shortness of breath, diarrhea, jaundice, or fatigue. Regular monitoring helps catch problems early. Discuss the potential benefits and risks with your healthcare provider before starting treatment.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
